ULTRA LOW DOSE (<2 mg/day) showed no clear difference in leaving the study early: Any reason ‐ when compared with… compared with ANY DOSE ‐ short term (moderate certainty).
ULTRA LOW DOSE (<2 mg/day) showed no clear difference in mental state: 1. No clinically important improvement ‐ as measured… compared with ANY DOSE ‐ short term (moderate certainty).
STANDARD‐LOWER DOSE (greater than or equal to 4‐<6 mg/day) showed no clear difference in leaving the study early: Any reasons ‐ when compared with ultra low… compared with ANY DOSE ‐ short term (moderate certainty).
ULTRA LOW DOSE (<2 mg/day) showed no clear difference in mental state: 1. No clinically important improvement ‐ as measured… compared with ANY DOSE ‐ short term (moderate certainty).
HIGH DOSE (greater than or equal to 10 mg/day) probably leads to lower leaving the study early: insufficient response ‐ When compared with… compared with ANY DOSE ‐ short term (moderate certainty).
STANDARD‐HIGHER DOSE (greater than or equal to 6‐<10 mg/day) probably leads to lower leaving the study early: insufficient response ‐ When compared with… compared with ANY DOSE ‐ short term (moderate certainty).
ULTRA LOW DOSE (<2 mg/day) showed no clear difference in leaving the study early: Any reason ‐ when compared with high dose… compared with ANY DOSE ‐ short term (moderate certainty).
STANDARD‐LOWER DOSE (greater than or equal to 4‐<6 mg/day) showed no clear difference in mental state: No clinically important improvement ‐ PANSS ‐ when… compared with ANY DOSE ‐ short term (moderate certainty).
HIGH DOSE (greater than or equal to 10 mg/day) showed no clear difference in mental state: 1. No clinically important improvement ‐ PANSS ‐ when… compared with ANY DOSE ‐ short term (moderate certainty).
STANDARD‐HIGHER DOSE (greater than or equal to 6‐<10 mg/day) probably leads to lower mental state: 1. No clinically important improvement ‐ PANSS ‐ when… compared with ANY DOSE ‐ short term (moderate certainty).